Key takeaways
Darifenacin ER (formerly branded as Enablex) and Myrbetriq (mirabegron) are both used to treat overactive bladder (OAB) symptoms, but they work in different ways and have distinct characteristics. Darifenacin ER is a urinary antispasmodic that relaxes bladder muscles by blocking certain receptors, while Myrbetriq is a beta-3 adrenergic agonist that helps the bladder hold more urine by activating specific proteins. Darifenacin ER and Myrbetriq are both available in generic forms, making them more cost-effective option. Myrbetriq can be used in children aged 3 and older for neurogenic detrusor overactivity (NDO), while darifenacin ER is only for adults. Common side effects of darifenacin ER include dry mouth and constipation, whereas Myrbetriq can cause high blood pressure and urinary tract infections. Additionally, darifenacin ER is generally not recommended for those 65 or older due to increased risk of dizziness and drowsiness, while Myrbetriq might be safer for older adults.
